<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002377</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT02002377</nct_id>
  </id_info>
  <brief_title>Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections</brief_title>
  <acronym>SHIFT-2</acronym>
  <official_title>The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Routine Ranibizumab Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in
      patients with wet age related macular degeneration who have incomplete response with
      routineranibizumab treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate enrollment due to investigational product becoming newly available on the Canadian
    market soon after study start
  </why_stopped>
  <start_date type="Actual">April 17, 2014</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">February 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>'OCT defined success' defined by no presence of intra or sub retinal fluid on SDOCT</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>'OCT defined success' defined by no presence of intra or sub retinal fluid on SDOCT</measure>
    <time_frame>16 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central retinal thickness (CRT)</measure>
    <time_frame>Weeks 12, 16, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity</measure>
    <time_frame>Week 12, 16, and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks</description>
    <arm_group_label>Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Note: Subjects must meet all of the following inclusion criteria to be eligible for
        enrollment into the study

          1. Age &gt;50 years

          2. Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD
             including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein
             Angiography in the study eye

          3. Presence of intra or sub retinal fluid on SDOCT in the study eye

          4. Current treatment with uninterrupted routine (q35 +/- 7 days) ranibizumab started at
             least 3 months before Baseline (Week 0), having received at least 3 consecutive
             ranibizumab injections and no more than 24 injections maximum, with all ranibizumab
             injection intervals being 35 +/- 7 days apart

          5. ETDRS BCVA 20/30 and 20/320 (letter score of 78 to 25) in the study eye

        Exclusion Criteria:

        Subjects presenting with any of the following will not be included in the study:

          1. Presence of purely serous pigment epithelial detachment in the study eye

          2. Any scarring or fibrosis involving the center of the fovea in the study eye

          3. Prior ocular or systemic treatment/surgery for wet AMD other than ranibizumab IVI
             monthly (in study the eye)

          4. Prior prn or treat and extend treatment with ranibizumab IVI between 3 to 24 months
             before Baseline (Week 0) in the study eye

          5. Prior treatment with systemic anti-VEGF therapy within the last 6 months in the study
             eye

          6. History of vitreous hemorrhage within the last 6 months in the study eye

          7. Prior vitrectomy in the study eye

          8. History of retinal detachment in the study eye

          9. History of macular hole of stage 2 and above in the study eye

         10. Presence of retinal pigment epithelial tears or rips involving the macula in the study
             eye.

         11. Any intraocular or periocular surgery/invasive procedure during the previous 6 months
             except lid surgery in the study eye

         12. Prior trabeculectomy or other filtration surgery in the study eye

         13. Uncontrolled glaucoma (â‰¥ 25mmHg despite treatment with anti-glaucoma medications) in
             the study eye

         14. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a
             result of a yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.

         15. Scheduled for intraocular surgery during the study period in the study eye

         16. Concurrent retinal disease (i.e. diabetic retinopathy, retinal vein occlusion, retinal
             detachment, uveitis) in the study eye

         17. History of ocular or periocular infection/inflammation in the study eye within the
             last 4 weeks of screening

         18. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Brent, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajeev Muni, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calgary Retina Consultants</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H 0C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Retina Consultants</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 0X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Centre for Ambulatory Services</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8G 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital / Queen's</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivey Eye Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Retina Consultants</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7S 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age Related Macular Degeneration, wet</keyword>
  <keyword>aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

